India, Sept. 16 -- Sensorion has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission. The submission is a preliminary step in the company's evaluation of a potential U.S. initial public offering of its ordinary shares, including in the form of ADSs, and the listing of such ADSs on a U.S. national exchange.
Sensorion is a clinical-stage biotech company, which specializes in the development of therapies to restore, treat, and prevent hearing loss disorders. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: ed...